Myelopeptide-2 (MP-2) is an immunomodulator derived from porcine bone marrow cell culture supernatant. Myelopeptide-2 restores the mitotic reactivity of human T lymphocytes suppressed by HL-60 leukemia cell conditioned medium or measles virus. Myelopeptide-2 can be used in studies on tumor immunosuppression recovery and antiviral immunotherapy[1-4].
In vitro, phytohemagglutinin-stimulated T lymphocytes were incubated with 100μg/mL Myelopeptide-2 and HL-60 cell conditioned medium for 72 hours. Myelopeptide-2 restored T lymphocyte proliferative response. Myelopeptide-2 restored CD3 and CD4 antigen expression and CD25-positive cell proportion[5]. T lymphocytes were treated with 10-25μg/mL Myelopeptide-2 for 18-24 hours. Myelopeptide-2 restored T lymphocyte cytotoxic activity against P-388 leukemia cells[6].
In vivo, urethane-induced BALB/c mice received 10μg/mouse Myelopeptide-2 by intraperitoneal injection daily for 4 days. Myelopeptide-2 reduced the number of spontaneous lung adenomas. Urethane-induced BALB/c mice received 100μg/mouse Myelopeptide-2 by intraperitoneal injection for 25 days. Myelopeptide-2 reduced animal mortality and delayed the first appearance time of lung tumors[7]. Female mice transplanted with Ca-755 cells, Lewis cells, or S180 cells received 0.5mg/kg Myelopeptide-2 by subcutaneous injection once daily for 5 times, or 1mg/kg or 2mg/kg every 96 hours for 2 times. Myelopeptide-2 inhibited transplanted tumor growth[8].
References:[1] Petrov R. Myelopeptides: new immunoregulatory peptides. Allergy Proc. 1995 Jul-Aug;16(4):177-84.
[2] Sorokina NS, Starostina MV. Myelopeptides Reduce Morphine Tolerance in C57BL/6j Mice. Bull Exp Biol Med. 2021 Sep;171(5):623-626.
[3] Mikhailova AA, Belevskaya RG, Kalyuzhnaya M, et al. Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus. J Immunother. 2006 May-Jun;29(3):306-12.
[4] Svirshchevskaya EV, Belevskaya RG, Roslavtzeva TA, et al. Influence of Myelopeptides on IL-1 and IL-2 Activities. Russ J Immunol. 1997 Apr;2(1):29-36.
[5] Strelkov LA, Mikhailova AA, Sapozhnikov AM, et al. The bone marrow peptide (myelopeptide-2) abolishes suppression of T lymphocytes induced by human leukemia HL-60 cells. Immunol Lett. 1996 Jun;50(1-2):143-7.
[6] Khabarov SV, Gerasimova GK, Mikhailova AA, et al. Myelopeptide-2 Induces the Resistance of T-Lymphocytes to Tumor Suppression. Dokl Biol Sci. 2003;390:282-5.
[7] Mikhailova AA, Kirilina EA, Morozova OV, et al. Effect of Myelopeptide-2 on the Development of Spontaneous and Urethane-Induced Tumors in Mice. Bull Exp Biol Med. 2002 Jan;133(1):68-70.
[8] Fonina LA, Ovchinnikov MV, Gur'yanov SA, et al. Synthesis and Properties of the retro-Analogue of Myelopeptide MP-2. Russ J Bioorg Chem. 2005;31(3):210-5.